Page last updated: 2024-10-17

choline and Cirrhosis

choline has been researched along with Cirrhosis in 34 studies

Research Excerpts

ExcerptRelevanceReference
"Decreased choline intake is significantly associated with increased fibrosis in postmenopausal women with NAFLD."9.16Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. ( Colvin, RM; Diehl, A; Guerrerio, AL; Lavine, JE; Mohan, P; Molleston, JP; Murray, KF; Scheimann, AO; Schwartz, AK; Schwimmer, JB; Torbenson, MS, 2012)
"This study demonstrated that RGS4 promoted cardiac fibrosis and attenuated the anti-cardiac fibrosis of choline."8.02The association between RGS4 and choline in cardiac fibrosis. ( Du, Z; Fan, Z; Guo, J; Hang, P; Li, W; Sun, Y; Yu, J; Zhao, X, 2021)
"A high-choline diet exacerbates cardiac dysfunction, myocardial fibrosis, and inflammation in HFpEF mice, and 3,3-dimethyl-1-butanol ameliorates the high-choline diet-induced cardiac remodeling."7.96High-Choline Diet Exacerbates Cardiac Dysfunction, Fibrosis, and Inflammation in a Mouse Model of Heart Failure With Preserved Ejection Fraction. ( Li, X; Li, Y; Shuai, W; Wang, D; Wen, J; Xiang, J, 2020)
"Heart failure severity is significantly enhanced in mice fed diets supplemented with either choline or the gut microbe-dependent metabolite TMAO."7.83Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. ( Bhushan, S; Bradley, J; Hazen, SL; Lefer, DJ; Organ, CL; Otsuka, H; Polhemus, DJ; Tang, WH; Trivedi, R; Wang, Z; Wu, Y, 2016)
"1% methionine in HFCD diet suppressed body weight gain, which was lower than that with control diet."7.83Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice. ( Chiba, T; Itoh, T; Sato, Y; Suzuki, S; Umegaki, K, 2016)
"Quercetin (50 mg/kg) was given by oral route daily."5.38Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. ( González-Gallego, J; Marcolin, E; Marroni, N; San-Miguel, B; Tieppo, J; Tuñón, MJ; Vallejo, D, 2012)
"Decreased choline intake is significantly associated with increased fibrosis in postmenopausal women with NAFLD."5.16Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. ( Colvin, RM; Diehl, A; Guerrerio, AL; Lavine, JE; Mohan, P; Molleston, JP; Murray, KF; Scheimann, AO; Schwartz, AK; Schwimmer, JB; Torbenson, MS, 2012)
" Previously, we reported a dietary mouse NASH model with a choline-deficient, methionine-lowered, L-amino-acid-defined, high-fat diet containing shortening without trans fatty acids (CDAA-HF-T[-]), which rapidly induces fibrosis and proliferative lesions in the liver."4.31Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes. ( Abe, A; Miyajima, K; Nakae, D; Nakane, S; Suzuki-Kemuriyama, N; Yuki, M, 2023)
" High circulating levels of TMAO and its dietary precursor, choline, predict increased risk for development of CKD in apparently healthy subjects, and studies in mice fed TMAO or choline suggest that TMAO can contribute to kidney impairment and renal fibrosis."4.02Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. ( Charugundla, S; Guo, F; Hazen, SL; Jia, X; Kaczor-Urbanowicz, KE; Lusis, AJ; Magyar, C; Miikeda, A; Nicholas, SB; Pellegrini, M; Shih, DM; Wang, Z; Zhang, W; Zhou, Z; Zuckerman, J, 2021)
"This study demonstrated that RGS4 promoted cardiac fibrosis and attenuated the anti-cardiac fibrosis of choline."4.02The association between RGS4 and choline in cardiac fibrosis. ( Du, Z; Fan, Z; Guo, J; Hang, P; Li, W; Sun, Y; Yu, J; Zhao, X, 2021)
"Gut microbial metabolism of dietary choline, a nutrient abundant in a Western diet, produces trimethylamine (TMA) and the atherothrombosis- and fibrosis-promoting metabolite TMA-N-oxide (TMAO)."3.96Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. ( Buffa, JA; DiDonato, JA; Gupta, N; Hazen, SL; Ho, KJ; Li, L; Roberts, AB; Sangwan, N; Skye, SM; Tang, WHW; Varga, J, 2020)
"Background Patients at increased risk for coronary artery disease and adverse prognosis during heart failure exhibit increased levels of circulating trimethylamine N-oxide (TMAO), a metabolite formed in the metabolism of dietary phosphatidylcholine."3.96Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure. ( Goodchild, TT; Gupta, N; Hazen, SL; Lefer, DJ; Li, Z; Organ, CL; Polhemus, DJ; Sharp, TE; Tang, WHW, 2020)
"A high-choline diet exacerbates cardiac dysfunction, myocardial fibrosis, and inflammation in HFpEF mice, and 3,3-dimethyl-1-butanol ameliorates the high-choline diet-induced cardiac remodeling."3.96High-Choline Diet Exacerbates Cardiac Dysfunction, Fibrosis, and Inflammation in a Mouse Model of Heart Failure With Preserved Ejection Fraction. ( Li, X; Li, Y; Shuai, W; Wang, D; Wen, J; Xiang, J, 2020)
"Heart failure severity is significantly enhanced in mice fed diets supplemented with either choline or the gut microbe-dependent metabolite TMAO."3.83Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. ( Bhushan, S; Bradley, J; Hazen, SL; Lefer, DJ; Organ, CL; Otsuka, H; Polhemus, DJ; Tang, WH; Trivedi, R; Wang, Z; Wu, Y, 2016)
" The aim of the present study was to elucidate the role of the TLR4‑dependent signaling pathway, and examine the effect of pioglitazone on hepatic fibrosis, through modulation of the TLR4 pathway in a mouse model of nutritional fibrotic steatohepatitis."3.83TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. ( Du, J; Kong, L; Nan, Y; Niu, X; Wang, R; Zhang, Y; Zhao, S, 2016)
"1% methionine in HFCD diet suppressed body weight gain, which was lower than that with control diet."3.83Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice. ( Chiba, T; Itoh, T; Sato, Y; Suzuki, S; Umegaki, K, 2016)
"We found that concentrations of LPA and lysophosphatidylcholine accumulated in the effluent in the swollen pelvis of the ligated kidney of unilateral ureteral obstruction rats were much higher than those in the urinary bladder."3.77Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. ( Adachi, M; Morishige, J; Nikawadori, M; Tokumura, A; Tsutsumi, T, 2011)
"Expression of cyclooxygenase (COX)-2 protein during rat hepatocarcinogenesis associated with fatty change, fibrosis, cirrhosis and oxidative DNA damage, caused by a choline-deficient, L-amino acid-defined (CDAA) diet were investigated in F344 male rats, along with the chemopreventive efficacy of the specific COX-2 inhibitor, nimesulide (NIM)."3.71Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. ( Denda, A; Kishida, H; Kitayama, W; Konishi, Y; Kusuoka, O; Murata, A; Nakae, D; Sasaki, Y; Takagi, H; Tsujiuchi, T; Tsutsumi, M, 2002)
"Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of liver damage directly related to diabetes, obesity, and metabolic syndrome."1.91(Pro)Renin Receptor Antagonism Attenuates High-Fat-Diet-Induced Hepatic Steatosis. ( Cooper, SG; Feng Earley, Y; Gayban, AJB; Kleemann, R; Regalado, E; Souza, LAC, 2023)
"While NKT-cell involvement in steatohepatitis is debated, discrepancies may stem from varied mouse strains used, predominantly C57BL6/J with Th1-dominant responses."1.91Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice. ( Andrés-Sánchez, N; Colell, A; Cuño-Gómiz, C; de Gregorio, E; Marí, M; Morales, A; Rider, P; Tutusaus, A, 2023)
"The pathogenesis of liver fibrosis requires activation of hepatic stellate cells (HSCs); once activated, HSCs lose intracellular fatty acids but the role of fatty acid oxidation and carnitine palmitoyltransferase 1A (CPT1A) in this process remains largely unexplored."1.72Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. ( Alonso, C; Crespo, J; Cubero, FJ; da Silva Lima, N; Delgado, TC; Dieguez, C; Fernandez, U; Filliol, AA; Fondevila, MF; Gonzalez-Rellan, MJ; Heras, V; Herrero, L; Iglesias, C; Iruzubieta, P; López, M; Martinez-Chantar, ML; Mato, JM; Mayo, R; Millet, O; Nogueiras, R; Novoa, E; Parracho, T; Porteiro, B; Prevot, V; Schwabe, RF; Schwaninger, M; Senra, A; Serra, D; Varela-Rey, M; Woodhoo, A, 2022)
"Autophagy affects NAFLD by improving steatosis."1.72Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity. ( Xin, SL; Yu, YY, 2022)
"Nonalcoholic steatohepatitis has emerged as a major cause of liver diseases with no effective therapies."1.56The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates. ( Chen, J; Cui, A; Gao, J; Han, J; Ji, S; Li, J; Li, Y; Liu, Z; Ma, F; Ma, X; Tai, P; Wang, G; Wang, T; Xue, Y, 2020)
"Choline treatment may represent a new therapeutic strategy for optimizing myocardial metabolism in the context of hypertrophy and heart failure."1.51Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway. ( Cui, YL; Lu, Y; Wu, Q; Xu, M; Xue, RQ; Yong, SY; Yu, XJ; Zang, WJ; Zhao, M; Zuo, XT, 2019)
"Although therapeutic intervention for nonalcoholic steatohepatitis (NASH) at an early stage is important owing to the progressive nature of the disease, diagnosis using noninvasive methods remains difficult."1.40Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. ( Fujita, K; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Saito, S; Sekino, Y; Shinohara, Y; Taguri, M; Takahashi, J; Tomeno, W; Toshima, G; Wada, K; Yoneda, M, 2014)
"Quercetin (50 mg/kg) was given by oral route daily."1.38Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. ( González-Gallego, J; Marcolin, E; Marroni, N; San-Miguel, B; Tieppo, J; Tuñón, MJ; Vallejo, D, 2012)
"Thus, effective treatment of fibrosis in inflammatory bowel disease may require early and complete blockade of NF-kappaB with particular attention to specific proinflammatory and profibrogenic genes that remain active at low levels of NF-kappaB."1.34Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. ( Chakravarti, S; Wu, F, 2007)
"Nonalcoholic steatohepatitis (NASH) may cause fibrosis, cirrhosis, and hepatocellular carcinoma (HCC); however, the exact mechanism of disease progression is not fully understood."1.33Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Kojima, H; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2006)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.94)18.7374
1990's0 (0.00)18.2507
2000's3 (8.82)29.6817
2010's12 (35.29)24.3611
2020's18 (52.94)2.80

Authors

AuthorsStudies
Fondevila, MF1
Fernandez, U1
Heras, V1
Parracho, T1
Gonzalez-Rellan, MJ1
Novoa, E1
Porteiro, B1
Alonso, C1
Mayo, R1
da Silva Lima, N1
Iglesias, C1
Filliol, AA1
Senra, A1
Delgado, TC1
Woodhoo, A1
Herrero, L1
Serra, D1
Prevot, V1
Schwaninger, M1
López, M1
Dieguez, C1
Millet, O1
Mato, JM1
Cubero, FJ1
Varela-Rey, M1
Iruzubieta, P1
Crespo, J1
Martinez-Chantar, ML1
Schwabe, RF1
Nogueiras, R1
Xin, SL1
Yu, YY1
Zhao, M2
Ma, L1
Honda, T1
Kato, A1
Ohshiro, T1
Yokoyama, S1
Yamamoto, K1
Ito, T1
Imai, N1
Ishizu, Y1
Nakamura, M1
Kawashima, H1
Tsuji, NM1
Ishigami, M1
Fujishiro, M1
Kong, W1
Tang, Y1
Liu, L2
Zhang, G1
Liu, Y1
Liu, J1
Zan, K1
Lei, W1
Li, Y3
Wang, Y1
Zuo, T1
Jin, H1
Ma, S1
Aljobaily, N1
Krutsinger, K1
Viereckl, MJ1
Joly, R1
Menlove, B1
Cone, B1
Suppes, A1
Han, Y1
Gayban, AJB1
Souza, LAC1
Cooper, SG1
Regalado, E1
Kleemann, R1
Feng Earley, Y1
Zhen, Q1
Liang, Q1
Wang, H1
Zheng, Y1
Lu, Z1
Bian, C1
Zhao, X2
Guo, X1
Suzuki-Kemuriyama, N1
Abe, A1
Nakane, S1
Yuki, M1
Miyajima, K1
Nakae, D2
Cuño-Gómiz, C1
de Gregorio, E1
Tutusaus, A1
Rider, P1
Andrés-Sánchez, N1
Colell, A1
Morales, A1
Marí, M1
Gupta, N2
Buffa, JA1
Roberts, AB1
Sangwan, N1
Skye, SM1
Li, L1
Ho, KJ1
Varga, J1
DiDonato, JA1
Tang, WHW2
Hazen, SL4
Cui, A1
Li, J1
Ji, S1
Ma, F1
Wang, G1
Xue, Y1
Liu, Z1
Gao, J1
Han, J1
Tai, P1
Wang, T1
Chen, J1
Ma, X1
Organ, CL2
Li, Z1
Sharp, TE1
Polhemus, DJ2
Goodchild, TT1
Lefer, DJ2
Shuai, W1
Wen, J1
Li, X1
Wang, D1
Xiang, J1
Esposito, G1
Schiattarella, GG1
Leclère, PS1
Rousseau, D1
Patouraux, S1
Guérin, S1
Bonnafous, S1
Gréchez-Cassiau, A1
Ruberto, AA1
Luci, C1
Subramaniam, M1
Tran, A1
Delaunay, F1
Gual, P1
Teboul, M1
Zhang, W1
Miikeda, A1
Zuckerman, J1
Jia, X1
Charugundla, S1
Zhou, Z1
Kaczor-Urbanowicz, KE1
Magyar, C1
Guo, F1
Wang, Z2
Pellegrini, M1
Nicholas, SB1
Lusis, AJ1
Shih, DM1
Guo, J1
Hang, P1
Yu, J1
Li, W1
Sun, Y1
Fan, Z1
Du, Z1
Xu, M1
Xue, RQ1
Lu, Y1
Yong, SY1
Wu, Q1
Cui, YL1
Zuo, XT1
Yu, XJ1
Zang, WJ1
Xiao, J1
Wang, F1
Liong, EC1
So, KF1
Tipoe, GL1
Trump, T1
Luchey, AM1
Hogg, J1
Mattes, MD1
Imajo, K1
Yoneda, M1
Fujita, K1
Kessoku, T1
Tomeno, W1
Ogawa, Y1
Shinohara, Y1
Sekino, Y1
Mawatari, H1
Nozaki, Y1
Kirikoshi, H1
Taguri, M1
Toshima, G1
Takahashi, J1
Saito, S1
Wada, K1
Nakajima, A1
Shimozono, R1
Asaoka, Y1
Yoshizawa, Y1
Aoki, T1
Noda, H1
Yamada, M1
Kaino, M1
Mochizuki, H1
Chen, R1
Wang, Q1
Song, S1
Liu, F1
He, B1
Gao, X1
Otsuka, H1
Bhushan, S1
Bradley, J1
Trivedi, R1
Tang, WH1
Wu, Y1
Du, J1
Niu, X1
Wang, R1
Zhao, S1
Kong, L1
Zhang, Y1
Nan, Y1
Chiba, T1
Suzuki, S1
Sato, Y1
Itoh, T1
Umegaki, K1
Tsutsumi, T1
Adachi, M1
Nikawadori, M1
Morishige, J1
Tokumura, A1
Guerrerio, AL1
Colvin, RM1
Schwartz, AK1
Molleston, JP1
Murray, KF1
Diehl, A1
Mohan, P1
Schwimmer, JB1
Lavine, JE1
Torbenson, MS1
Scheimann, AO1
Marcolin, E1
San-Miguel, B1
Vallejo, D1
Tieppo, J1
Marroni, N1
González-Gallego, J1
Tuñón, MJ1
OHTA, Y1
ZAKI, FG1
HOFFBAUER, FW1
Kitade, M1
Yoshiji, H1
Kojima, H1
Ikenaka, Y1
Noguchi, R1
Kaji, K1
Yoshii, J1
Yanase, K1
Namisaki, T1
Asada, K1
Yamazaki, M1
Tsujimoto, T1
Akahane, T1
Uemura, M1
Fukui, H1
Wu, F1
Chakravarti, S1
Denda, A1
Kitayama, W1
Murata, A1
Kishida, H1
Sasaki, Y1
Kusuoka, O1
Tsujiuchi, T1
Tsutsumi, M1
Takagi, H1
Konishi, Y1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635]Phase 3173 participants (Actual)Interventional2005-09-30Completed
Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)[NCT00063622]Phase 3247 participants (Actual)Interventional2005-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Body Mass Index

(NCT00063635)
Timeframe: baseline and 96 weeks

Interventionkg/m-squared (Mean)
Metformin1.3
Vitamin E2.1
Placebo1.9

Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment

Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionunits on a scale (Mean)
Metformin-1.1
Vitamin E-1.8
Placebo-0.7

Change in QOL- Psychosocial Health

Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionunits on a scale (Mean)
Metformin4.0
Vitamin E6.0
Placebo5.6

Change in Quality of Life (QOL) Scores- Physical Health

Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionunits on a scale (Mean)
Metformin5.4
Vitamin E7.6
Placebo5.4

Change in Serum Aspartate Aminotransferase (AST)

(NCT00063635)
Timeframe: baseline and 96 weeks

InterventionIU/L (Mean)
Metformin-21.5
Vitamin E-22.8
Placebo-20.4

Change in Serum Vitamin E Levels

Change in alpha-Tocopherol (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionmg/L (Mean)
Metformin-0.5
Vitamin E9.4
Placebo-0.9

Number of Participants With Improvement in Ballooning Degradation Score

Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin22
Vitamin E22
Placebo10

Number of Participants With Improvement in Liver Fibrosis Score

Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin22
Vitamin E18
Placebo19

Number of Participants With Improvement in Lobular Inflammation Score

Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin23
Vitamin E22
Placebo20

Number of Participants With Improvement in Steatosis Score

Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin26
Vitamin E27
Placebo19

Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L

The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin9
Vitamin E15
Placebo10

Number of Participants With Improvement in Fibrosis

Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis. (NCT00063622)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Pioglitazone31
Vitamin E33
Placebo22

Number of Participants With Improvement in Hepatocellular Ballooning

Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning. (NCT00063622)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Pioglitazone31
Vitamin E40
Placebo21

Number of Participants With Improvement in Lobular Inflammation

Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation. (NCT00063622)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Pioglitazone41
Vitamin E43
Placebo25

Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and After 96 Weeks of Treatment.

Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. (NCT00063622)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Pioglitazone27
Vitamin E36
Placebo16

Number of Participants With Improvement in Steatosis

Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis. (NCT00063622)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Pioglitazone48
Vitamin E43
Placebo22

Number of Participants With Resolution of Definite Nonalcoholic Steatohepatitis

The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis. (NCT00063622)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Pioglitazone33
Vitamin E29
Placebo15

Reviews

1 review available for choline and Cirrhosis

ArticleYear
Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.
    Ultrasound in medicine & biology, 2022, Volume: 48, Issue:12

    Topics: Animals; Biomarkers; Choline; Fibrosis; Liver; Liver Cirrhosis; Male; Methionine; Non-alcoholic Fatt

2022

Trials

1 trial available for choline and Cirrhosis

ArticleYear
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se

2012
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se

2012
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se

2012
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se

2012

Other Studies

32 other studies available for choline and Cirrhosis

ArticleYear
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis.
    Journal of hepatology, 2022, Volume: 77, Issue:1

    Topics: Animals; Carnitine O-Palmitoyltransferase; Choline; Fatty Acids; Fibrosis; Hepatic Stellate Cells; H

2022
Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2022, Volume: 54, Issue:8

    Topics: Animals; Autophagy; Choline; Fibrosis; Inflammation; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic

2022
Astaxanthin Attenuates Nonalcoholic Steatohepatitis with Downregulation of Osteoprotegerin in Ovariectomized Mice Fed Choline-Deficient High-Fat Diet.
    Digestive diseases and sciences, 2023, Volume: 68, Issue:1

    Topics: Animals; Choline; Diet; Diet, High-Fat; Down-Regulation; Estrogens; Female; Fibrosis; Humans; Liver;

2023
Integrative Metabolomics and Proteomics Detected Hepatotoxicity in Mice Associated with Alkaloids from
    Toxins, 2022, 11-05, Volume: 14, Issue:11

    Topics: Alkaloids; Animals; Chemical and Drug Induced Liver Injury; Choline; Eupatorium; Fibrosis; Glyceroph

2022
Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
    Nutrients, 2022, Dec-30, Volume: 15, Issue:1

    Topics: Animals; Body Weight; Choline; Choline Deficiency; Diet; Fibrosis; Humans; Inflammation; Liver; Live

2022
(Pro)Renin Receptor Antagonism Attenuates High-Fat-Diet-Induced Hepatic Steatosis.
    Biomolecules, 2023, 01-10, Volume: 13, Issue:1

    Topics: Animals; Choline; Diet, High-Fat; Fibrosis; Lipids; Liver; Methionine; Mice; Mice, Inbred C57BL; Non

2023
Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Animals; Choline; Choline Deficiency; Diabetes Mellitus, Type 2; Diet; Fibrosis; Inflammation; Methi

2023
Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
    PloS one, 2023, Volume: 18, Issue:8

    Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline; Choline D

2023
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Biology of sex differences, 2023, Nov-14, Volume: 14, Issue:1

    Topics: Animals; Choline; Diet, High-Fat; Fatty Liver; Female; Fibrosis; Humans; Inflammation; Liver Cirrhos

2023
Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.
    Arteriosclerosis, thrombosis, and vascular biology, 2020, Volume: 40, Issue:5

    Topics: Animals; Bacteria; Bacterial Proteins; Choline; Disease Models, Animal; Enzyme Inhibitors; Fibrosis;

2020
The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates.
    Diabetes, 2020, Volume: 69, Issue:8

    Topics: Animals; Body Weight; Cell Line; Choline; Fibroblast Growth Factors; Fibrosis; Inflammation; Liver;

2020
Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure.
    Journal of the American Heart Association, 2020, 05-18, Volume: 9, Issue:10

    Topics: Animals; Bacteria; Bacterial Proteins; Choline; Disease Models, Animal; Down-Regulation; Enzyme Inhi

2020
High-Choline Diet Exacerbates Cardiac Dysfunction, Fibrosis, and Inflammation in a Mouse Model of Heart Failure With Preserved Ejection Fraction.
    Journal of cardiac failure, 2020, Volume: 26, Issue:8

    Topics: Animals; Choline; Diet; Fibrosis; Heart Failure; Humans; Inflammation; Mice; Mice, Inbred C57BL; Str

2020
Feeding Diastolic Dysfunction: Is It a Bug?
    Journal of cardiac failure, 2020, Volume: 26, Issue:8

    Topics: Animals; Choline; Diet; Fibrosis; Heart Diseases; Heart Failure; Inflammation; Mice; Stroke Volume

2020
MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice.
    Scientific reports, 2020, 07-22, Volume: 10, Issue:1

    Topics: Animals; Apoptosis; Biomarkers; Caspase 3; Cells, Cultured; Choline; Circadian Rhythm; Diet; Disease

2020
Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.
    Scientific reports, 2021, 01-12, Volume: 11, Issue:1

    Topics: Adenine; Albuminuria; Animals; Cardiomegaly; Choline; Disease Models, Animal; Female; Fibroblast Gro

2021
The association between RGS4 and choline in cardiac fibrosis.
    Cell communication and signaling : CCS, 2021, 04-23, Volume: 19, Issue:1

    Topics: Animals; Choline; Fibroblasts; Fibrosis; Gene Silencing; Male; MAP Kinase Signaling System; Mice; My

2021
Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway.
    Cardiovascular research, 2019, 03-01, Volume: 115, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Choline; Disease Models, Animal; Energy Met

2019
Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model.
    International journal of biological macromolecules, 2018, Volume: 120, Issue:Pt B

    Topics: Animals; Antioxidants; Apoptosis; Choline; Diet; Disease Models, Animal; Drugs, Chinese Herbal; Fema

2018
Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C-Choline Positron Emission and Computed Tomography.
    Practical radiation oncology, 2019, Volume: 9, Issue:1

    Topics: Bone and Bones; Bone Neoplasms; Carbon Radioisotopes; Choline; Fibrosis; Humans; Male; Middle Aged;

2019
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.
    Journal of gastroenterology, 2014, Volume: 49, Issue:2

    Topics: Administration, Oral; Adult; Aged; Area Under Curve; Case-Control Studies; Choline; Fasting; Fatty L

2014
Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
    Molecular pharmacology, 2013, Volume: 84, Issue:1

    Topics: Amino Acids; Animals; Anti-Inflammatory Agents; Antioxidants; Binding Sites; Cell Line; Choline; Die

2013
Protective role of autophagy in methionine-choline deficient diet-induced advanced nonalcoholic steatohepatitis in mice.
    European journal of pharmacology, 2016, Jan-05, Volume: 770

    Topics: Animals; Autophagy; Choline; Diet; Endoplasmic Reticulum Stress; Fibrosis; Liver; Methionine; Mice;

2016
Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure.
    Circulation. Heart failure, 2016, Volume: 9, Issue:1

    Topics: Animals; Bacteria; Cardiomegaly; Choline; Diet; Disease Models, Animal; Disease Progression; Fibrosi

2016
TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice.
    Molecular medicine reports, 2016, Volume: 13, Issue:3

    Topics: Animals; Chemokines; Choline; Diet; Down-Regulation; Fibrosis; Inflammation; Liver; Liver Cirrhosis;

2016
Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Animals; Biomarkers; Choline; Diet, High-Fat; Fibrosis; Gene Expression; Glucose Tolerance Test; Lip

2016
Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction.
    Life sciences, 2011, Aug-01, Volume: 89, Issue:5-6

    Topics: Animals; Blotting, Western; Body Fluids; Choline; Chromatography, Liquid; Extracellular Space; Fibro

2011
Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.
    The Journal of nutrition, 2012, Volume: 142, Issue:10

    Topics: Animals; Biomarkers; Choline; Choline Deficiency; Collagen Type I; Collagen Type III; Cyclooxygenase

2012
Fatty cirrhosis in the rat. V. Regression upon return to normal diet.
    The American journal of pathology, 1963, Volume: 42

    Topics: Animals; Choline; Diet; Fatty Liver; Fibrosis; Liver Cirrhosis; Liver Cirrhosis, Experimental; Rats

1963
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Choline; Disease Models, Animal; Disease Progression; Fatty Live

2006
Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis.
    Journal of immunology (Baltimore, Md. : 1950), 2007, Nov-15, Volume: 179, Issue:10

    Topics: Animals; Aziridines; CD4-Positive T-Lymphocytes; Choline; Chronic Disease; Colitis, Ulcerative; Croh

2007
Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.
    Carcinogenesis, 2002, Volume: 23, Issue:2

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Amino Acids; Animal Nutritional Physiological Phenomena; Animals; Antic

2002